TAVI: FDA adds 'valve-in-valve' indication for Medtronic's CoreValve – MassDevice

Medtronic (NYSE:MDT) today scored a double for its CoreValve replacement heart valve, after Japanese regulators approved the transcatheter aortic valve implant and the FDA expanded its indication to include "valve-in-valve" procedures.